| 4.62 0.14 (3.13%) | 09-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.53 |
1-year : | 5.85 |
| Resists | First : | 4.74 |
Second : | 5.01 |
| Pivot price | 4.52  |
|||
| Supports | First : | 4.3 |
Second : | 3.58 |
| MAs | MA(5) : | 4.53 |
MA(20) : | 4.57 |
| MA(100) : | 4.08 |
MA(250) : | 3.41 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 46.3 |
D(3) : | 38 |
| RSI | RSI(14): 53 |
|||
| 52-week | High : | 7.07 | Low : | 1.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TMCI ] has closed below upper band by 14.8%. Bollinger Bands are 71% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.64 - 4.66 | 4.66 - 4.69 |
| Low: | 4.34 - 4.38 | 4.38 - 4.41 |
| Close: | 4.57 - 4.62 | 4.62 - 4.67 |
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Sat, 26 Sep 2026
Bank of America Corp DE Acquires 3,305,100 Shares of Treace Medical Concepts, Inc. $TMCI - MarketBeat
Sat, 26 Sep 2026
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Thu, 24 Sep 2026
Treace Medical Concepts, Inc. (TMCI) Stock Price, News, Quote & History - ca.finance.yahoo.com
Wed, 23 Sep 2026
Treace Medical Concepts, Inc. (TMCI) stock price, news, quote and history - Yahoo Finance UK
Sun, 20 Sep 2026
Treace Medical Looks Unlikely To Recover, A Founder-Led Broken Growth Story (NASDAQ:TMCI) - Seeking Alpha
Tue, 15 Sep 2026
Treace Medical Concepts to Showcase New Foot and Ankle Innovations and Clinical Data at AOFAS 2026 - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 65 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 25.2 (%) |
| Held by Institutions | 49.6 (%) |
| Shares Short | 1,600 (K) |
| Shares Short P.Month | 1,840 (K) |
| EPS | -0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.03 |
| Profit Margin | -29 % |
| Operating Margin | -33 % |
| Return on Assets (ttm) | -17.4 % |
| Return on Equity (ttm) | -72 % |
| Qtrly Rev. Growth | -4.2 % |
| Gross Profit (p.s.) | 2.5 |
| Sales Per Share | 3.15 |
| EBITDA (p.s.) | -0.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -5.03 |
| PEG Ratio | 0 |
| Price to Book value | 4.44 |
| Price to Sales | 1.46 |
| Price to Cash Flow | -20.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|